LCTX - Lineage Cell Therapeutics - Stock Forecast

Coverage Performance Price Targets & Ratings Chart Insider Trading

LCTX is currently covered by 1 analysts with an average price target of $7.08. This is a potential upside of $5.98 (543.64%) from yesterday's end of day stock price of $1.1.

Lineage Cell Therapeutics's activity chart (see below) currently has 0 price targets and 5 ratings on display. The stock rating distribution of LCTX is 100% BUY.

Stock Analyst Price Targets - Review

Highest price target for LCTX is $7, Lowest price target is $7, average price target is $7.08.

Most recent stock forecast was given by JOSEPH PANTGINIS from HCWAINWRIGHT on 13-Feb-2024. First documented stock forecast 10-Mar-2023.

Best performing analysts who are covering LCTX - Lineage Cell Therapeutics:

Joseph Pantginis

Currently out of the existing stock ratings of LCTX, 5 are a BUY (100%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

7

$5.9 (536.36%)

7

2 months 12 days ago

0/5 (0%)

$5.98 (586.27%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is LCTX (Lineage Cell Therapeutics) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on LCTX (Lineage Cell Therapeutics) with a proven track record?

JOSEPH PANTGINIS

Which analyst has the most public recommendations on LCTX (Lineage Cell Therapeutics)?

Joseph Pantginis has 15 price targets and 12 ratings on LCTX

Which analyst is the currently most bullish on LCTX (Lineage Cell Therapeutics)?

Joseph Pantginis with highest potential upside - $5.9

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?